Blockchain Press Releases
Clinical Trial Imaging Market worth $1.9 billion | MarketsandMarkets
CHICAGO, Aug. 18, 2023 /PRNewswire/ — In the near future, the Clinical Trial Imaging industry is poised to undergo a transformative evolution, driven by rapid advancements in medical imaging technology, data analytics, and regulatory frameworks. Cutting-edge imaging modalities such as functional MRI, molecular imaging, and advanced PET-CT scans will enable researchers to delve deeper into the intricacies of disease progression and treatment response, providing more nuanced and personalized insights. Integration of artificial intelligence and machine learning algorithms will streamline image analysis, facilitating quicker and more accurate diagnoses, patient stratification, and endpoint determination. Additionally, seamless collaboration between pharmaceutical companies, research institutions, and imaging facilities, coupled with standardized protocols, will enhance data sharing and accelerate clinical trial timelines. However, this expansion will also bring challenges in terms of data security, protocol harmonization, and ensuring the reliability of novel imaging techniques. In essence, the Clinical Trial Imaging industry’s imminent future promises to revolutionize the landscape of medical research, enhancing the efficiency and effectiveness of drug development while ultimately benefiting patient outcomes.
Clinical Trial Imaging Market in terms of revenue was estimated to be worth $1.3 billion in 2023 and is poised to reach $1.9 billion by 2028, growing at a CAGR of 7.8% from 2023 to 2028 according to a new report by MarketsandMarkets™. Rising expenditures in research and development, the expansion of the pharmaceutical and biotechnology sectors, and the proliferation of Contract Research Organizations (CROs) constitute several additional factors. Emerging economies like China, India, and Japan present attractive prospects for stakeholders engaged in the clinical trial imaging market.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=30446624
Browse in-depth TOC on “Clinical Trial Imaging Market”
111 – Tables
38 – Figures
179 – Pages
Clinical Trial Imaging Market Scope:
|
Report Coverage |
Details |
|
Market Revenue in 2023 |
$1.3 billion |
|
Estimated Value by 2028 |
$1.9 billion |
|
Growth Rate |
Poised to grow at a CAGR of 7.8% |
|
Market Size Available for |
2021–2028 |
|
Forecast Period |
2023–2028 |
|
Forecast Units |
Value (USD Billion) |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
Service & software, modality, therapeutic area, end user and region |
|
Geographies Covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
|
Report Highlights |
Updated financial information / product portfolio of players |
|
Key Market Opportunities |
Growth opportunities in emerging economies |
|
Key Market Drivers |
Rise in research and development expenditures |
The services segment accounted for the largest share of the clinical trial imaging market, by product and service segment, in 2022
Based on product, the clinical trial imaging market is segmented into services and software. In 2022, services accounted for the largest share of the global clinical trial imaging market. The large share of this segment can primarily be attributed to the high cost of imaging equipment, which has driven the outsourcing of imaging clinical trials by pharmaceutical, biotechnology, and medical device manufacturers to service providers.
Positron emission tomography segment to register the highest growth rate during the forecast period
The clinical trial imaging market is segmented into computed tomography, magnetic resonance imaging, ultrasound, positron emission tomography, X-ray, echocardiography and other modalities. In 2022, the positron emission tomography segment accounted for the highest growth rate. Technological expansions and the introduction of new tracers for cardiology, oncology, and neurology applications are expected to support the adoption of PET systems in clinical trial settings.
The oncology segment accounted for the largest share of the clinical trial imaging market, by therapeutic area segment, in 2022
Based on therapeutic area, the clinical trial imaging market has been segmented into oncology, infectious diseases, neurology, CVS, endocrinology, immunological disorder and other therapeutic area. In 2022, the oncology segment accounted for the largest share of the clinical trial imaging market. The dominant portion of this segment’s market share can be chiefly attributed to the extensive volume of oncology-related clinical trials, driven by the global increase in cancer incidence.
North America is the largest regional market for clinical trial imaging market
The global clinical trial imaging market is segmented into five major regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2022, North America accounted for the largest share of the clinical trial imaging market. The large share of this region can be attributed to the growing cutting-edge medical technologies, a mounting count of pharmaceutical and biotechnology enterprises, and substantial governmental investments in clinical research and development.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=30446624
Clinical Trial Imaging Market Dynamics:
Drivers:
- Increasing R&D spending
- Growth of pharmaceutical and biotechnology industries
- Increasing number of CROs
Restraints:
- High implementation cost of imaging systems
Opportunities:
- Growth opportunities in emerging economies
- Development of innovative imaging modalities, contrast agents, molecular probes, and radiopharmaceuticals
Challenges:
- High cost of clinical trials
Key Market Players:
The major players operating in this market are ICON plc. (Ireland), BioTelemetry Inc. (US), Biomedical Systems Corporation (US), Medpace Holdings, Inc. (US), IXICO plc. (UK), Resonance Health Ltd. (Australia), Radiant Sage LLC. (US), BioClinica Inc. (US), Intrinsic Imaging LLC. (US), Cardiovascular Imaging Technologies LLC. (US), Medical Metrics Inc. (US), Prism Clinical Imaging, Inc. (US), Boston Imaging Core Lab LLC. (US), anagram 4 clinical trials (Spain), Lyscaut Medical Imaging Company (Belgium), Calyx Group (UK), Bioseptive Inc. (Canada), ProScan Imaging LLC. (US), Micron Inc. (Japan), Imaging Endpoints LI, LLC (US), Perspectum Ltd. (UK), Pharmtrace klinische Entwicklung GmbH (Germany), WorldCare Clinical, LLC (US), Median Technologies (France) and Invicro. LLC. (US).
Recent Developments:
- In March 2023, ICON Plc. (Ireland) announced a strategic partnership with LEO Pharma (Denmark) to scale clinical trial execution that is patient-centric and cost effective, and which will support the company’s overall ambition of building one of the most effective and efficient clinical portfolio execution organisations in the industry.
- In March 2023, Clario (US), announced the launch of a cutting-edge cloud-based image viewer tool for sponsors and contract research organizations to view images related to their clinical trials.
- In May 2021 IXICO Plc. (UK) signed a contract with biopharmaceutical client IXICO to provide neuroimaging services for a Phase III clinical trial under this contract.
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=30446624
Clinical Trial Imaging Market Advantages:
- Enhanced Decision Making: Imaging technologies allow researchers and clinicians to visualize biological processes and disease progression in real-time. This enables more informed decision-making during clinical trials by providing objective and quantifiable data on treatment efficacy and safety.
- Early Endpoint Identification: Imaging enables the identification of early treatment responses and disease progression markers, enabling the early determination of trial endpoints. This leads to quicker assessment of treatment outcomes and potential for adaptive trial designs.
- Patient-Centric Approach: Imaging modalities like PET scans, MRIs, and CT scans provide a non-invasive way to monitor patient health, reducing the need for invasive procedures. This patient-centric approach improves participant comfort and compliance in clinical trials.
- Personalized Medicine: Advanced imaging techniques facilitate the identification of patient subgroups that respond better to specific treatments. This leads to the development of targeted therapies, enhancing treatment effectiveness and minimizing adverse effects.
- Efficient Drug Development: Imaging accelerates drug development by providing insights into a drug’s mechanism of action and its impact on disease pathways. This reduces the time and costs associated with traditional trial endpoints, contributing to faster market entry for new drugs.
- Objective Quantification: Imaging offers objective measurements of treatment effects, reducing subjectivity in data interpretation. This improves the robustness and credibility of trial results, enhancing the likelihood of regulatory approval.
- Global Collaboration: Digital imaging technology allows real-time sharing of data across geographical boundaries, facilitating collaboration among researchers, clinicians, and regulatory agencies. This leads to standardized protocols and increased harmonization across clinical trials.
- Regulatory Compliance: Well-established imaging techniques adhere to rigorous regulatory standards, ensuring the safety and ethical considerations of participants. This instills confidence in trial outcomes and supports regulatory approval processes.
- Longitudinal Monitoring: Imaging enables researchers to track disease progression and treatment response over time, providing insights into the long-term effects of interventions. This information is crucial for understanding chronic diseases and evaluating treatment durability.
- Translational Research: Clinical trial imaging bridges the gap between preclinical research and human studies, allowing researchers to validate findings in real-world patient populations. This aids in the translation of promising preclinical discoveries into effective clinical interventions.
In summary, the advantages of the Clinical Trial Imaging market lie in its ability to provide objective, precise, and timely data, enhancing the efficiency and success rate of drug development while ultimately benefiting patient care and medical advancements.
Related Reports:
CRO Services Market – Global Forecasts to 2028
Mice Model Market – Global Forecasts to 2028
Clinical Trial Supplies Market – Global Forecasts to 2028
Contrast Media Market – Global Forecasts to 2027
Diagnostic Imaging Market – Global Forecasts to 2026
About MarketsandMarkets™:
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/clinical-trials-imaging-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/clinical-trials-imaging.asp
Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/clinical-trial-imaging-market-worth-1-9-billion–marketsandmarkets-301904364.html
DUBAI, UAE, Nov. 28, 2024 /PRNewswire/ — Bybit, the world’s second-largest cryptocurrency exchange by trading volume, in collaboration with Blocks Scholes, released the latest weekly derivatives analytics report and uncovered signals indicating ETH’s rise above BTC in the past week.
Fueled by news of current U.S. SEC Chair Gary Gensler’s departure at the end of the Biden administration’s term, ETH performance has positively surprised investors. In particular, open interest in ETH perpetual has been on the rise. Several large-cap altcoins also benefited from Gensler’s announcement, anticipating less scrutiny upcoming January.
Key Insights:
ETH outperformed BTC in open interest: Perpetual swap data has seen a gradual decline in BTC open interest while ETH contracts increased. ETH has also been taking a bigger share of daily trading volumes in the past 6-month time frame despite an overall slower market this week. The optimism could be attributed to hopeful investors’ expectation of a more crypto-friendly SEC Chair after Gensler’s last day on Jan. 20, 2025.
BTC price in retreat: BTC price’s ebbing from the $100K mark has flattened the ATM volatility term structure, with short-tenor options dipping below 60%. This mirrors a pattern observed since the U.S. election. Lower realized volatility explains the drop, while open interest in calls and puts remains unchanged, demands for short-term options this week have stagnated.
ETH options – bullish sentiment in moderation: ETH options show slightly more bullish sentiment than BTC options. Markets have recalibrated after the post-election high, but call options remain in the lead in both trading volumes and open interests.
Access the Full Report:
Read the full report in context here.
#Bybit / #TheCryptoArk /#BybitResearch
About Bybit
Bybit is the world’s second-largest cryptocurrency exchange by trading volume, serving over 50 million users. Established in 2018, Bybit provides a professional platform where crypto investors and traders can find an ultra-fast matching engine, 24/7 customer service, and multilingual community support. Bybit is a proud partner of Formula One’s reigning Constructors’ and Drivers’ champions: the Oracle Red Bull Racing team.
For more details about Bybit, please visit Bybit Press
For media inquiries, please contact: [email protected]
For more information, please visit: https://www.bybit.com
For updates, please follow: Bybit’s Communities and Social Media
Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube
Photo – https://mma.prnewswire.com/media/2569395/Bybit_x_Block_Scholes_Derivatives_Report_ETH_Outperforms_BTC.jpg
Logo – https://mma.prnewswire.com/media/2267288/Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/bybit-x-block-scholes-derivatives-report-eth-outperforms-btc-302318387.html
GZIRA, Malta, Nov. 28, 2024 /PRNewswire/ — Popular iGaming content provider BGaming has secured a highly sought-after licence in Peru, marking a significant milestone in its expansion across LatAm.
BGaming’s technical system of gaming software and its engaging portfolio have been officially approved by the gambling regulator Mincetur, a national administrative authority which implements and oversees all aspects of online gaming and sports betting in Peru. By receiving the B2B certification, BGaming broadens its appeal with local licenced operators in the newly regulated market.
The licence also opens up more opportunities for BGaming to expand its business and strengthen its position in the wider LatAm region, where it has enjoyed significant attention in the last 12 months.
Marina Ostrovtsova, CEO at BGaming, said: “Securing the Peru licence marks a pivotal moment in BGaming’s global expansion. This certification not only strengthens our presence in Latin America but also underscores our commitment to bringing high-quality, immersive gaming experiences to new audiences.
“We are excited about the opportunities this will unlock, both in terms of growth and the reception of our slots in this new market.”
BGaming is a fast-growing iGaming content provider converting gambling into gaming. Thanks to an expert team and a player-driven approach, the studio creates innovative and engaging products featured on reputable platforms and 1,000+ online casinos worldwide. BGaming is the world’s first to support cryptocurrencies and offer Provably Fair games. Today the brand’s portfolio includes 100+ products with HD graphics and a clear user interface for every device. The studio is also known for its brand exclusives created in partnerships with leading operators in the industry.
Photo – https://mma.prnewswire.com/media/2568807/BGaming.jpg
View original content:https://www.prnewswire.co.uk/news-releases/bgaming-awarded-peru-supplier-licence-302317696.html
TAIPEI, Nov. 28, 2024 /PRNewswire/ — KryptoGO, a leader in Web3 financial infrastructure, has taken another groundbreaking step to ensure unparalleled user and enterprise safety by completing a rigorous security audit aligned with industry-leading methodologies. This milestone solidifies KryptoGO’s position alongside globally trusted platforms like 1Password, Metamask, and Trust Wallet, known for their exceptional security standards.
The audit, conducted with methodologies comparable to those used for 1Password—a benchmark in secure password management—focused on ensuring KryptoGO’s mobile applications, backend systems, and API endpoints meet the highest security standards. 1Password’s robust security features, such as end-to-end encryption, zero-knowledge architecture, and constant vulnerability testing, serve as the foundation for KryptoGO’s enhanced protection framework.
Demonstrating Excellence in Cybersecurity
KryptoGO has consistently showcased its expertise in security through achievements in prominent cybersecurity competitions and hackathons. Recognized for exceptional performance in events like 2024 BlazCTF, ETH Tokyo Hackathon, and ETH Taipei Hackathon, KryptoGO has solidified its reputation as a trusted innovator.
This audit marks another significant step forward, addressing potential vulnerabilities and reaffirming KryptoGO’s ability to safeguard user assets in an increasingly complex Web3 landscape. Notably, the findings resulted in a 50% reduction in vulnerabilities compared to prior assessments, demonstrating tangible progress in security hardening.
Why Security in Web3 Wallets Matters
In the Web3 ecosystem, wallets act as critical gateways, holding sensitive keys that grant users exclusive control over their digital assets. A single security lapse can lead to catastrophic consequences, including the loss of assets and the erosion of user trust.
Recognizing this, KryptoGO employs a multi-layered approach to private key management, ensuring the highest levels of security and reliability for its users:
- Device-Level Encryption: Private keys are encrypted with a Device Encryption Key and securely stored in the device’s protected environment (Keychain for iOS and Keystore for Android). Access to these keys is tightly controlled through biometric authentication, preventing unauthorized access.
- Password Protection with Argon2: For users who opt for password backups, KryptoGO utilizes Argon2-HMAC-SHA256 with 310,000 iterations to derive an Account Unlock Key (AUK). This industry-standard process, aligned with NIST guidelines, offers robust resistance to brute-force attacks while ensuring compatibility across a broad range of devices.
- Cloud Backup with Shamir’s Secret Sharing: To enhance convenience and accessibility, KryptoGO employs Shamir’s Secret Sharing Scheme (SSS) for password-free cloud backups. This approach splits private keys into multiple fragments (Key Shares) stored across diverse platforms like iCloud and Google Drive. Restoration is possible with any two fragments, ensuring data availability without compromising security.
These measures collectively address the most critical challenges in wallet security:
- Token Integrity: Robust lifecycle management prevents impersonation or unauthorized access.
- Advanced Encryption Standards: Sensitive wallet data and transactions are safeguarded by cutting-edge cryptographic techniques.
- Resilience Against Data Loss: Diverse and secure backup options ensure users can recover their wallets without fear of permanent loss.
- Access Control Enhancements: Multi-layered authentication mechanisms safeguard accounts.
- Secure APIs: Backdoor vulnerabilities and information leaks are actively prevented.
Results That Build Trust
The rigorous Cure53 audit, leveraging white-box and gray-box penetration testing, verified KryptoGO’s resilience against security threats. Cure53’s global reputation for securing critical systems further amplifies the credibility of KryptoGO’s security achievements. The resolution of key vulnerabilities identified during the audit, including token mismanagement and API access concerns, reflects KryptoGO’s dedication to continuous improvement and operational excellence.
Raising the Bar for Web3 Security
By achieving security certifications on par with 1Password and other leading platforms, KryptoGO has set a new benchmark for wallet safety in the Web3 era. These advancements empower users to confidently manage their digital assets while positioning KryptoGO as the trusted partner for enterprises seeking high standard and scalable blockchain solutions.
About KryptoGO
KryptoGO is a pioneer in Web3 solutions, providing secure, compliant, and user-friendly wallet services. Focused on stablecoin payment infrastructure and asset management, KryptoGO empowers businesses to seamlessly transition into the decentralized economy, backed by cutting-edge technology and industry best practices.
For more information on how KryptoGO can support your Web3 business needs, please visit www.kryptogo.com or contact us directly.
Media Contact: [email protected]
Learn more: www.kryptogo.com | X | LinkedIn
View original content:https://www.prnewswire.co.uk/news-releases/kryptogo-leads-the-way-with-top-tier-wallet-security-standards-302318212.html
-
Blockchain Press Releases7 days agoPolygon Collaborates with WSPN to Drive Stablecoin Adoption Through WUSD
-
Blockchain6 days ago
Trident Reports First Half 2024 Unaudited Financial Results
-
Blockchain7 days agoCoreNest Capital, Sologenic’s VC partner, invests in Texture, a U.S.-based broker-dealer, to launch SoloTex, a new platform for trading tokenized equities
-
Blockchain7 days agoBybit Strengthens Partnerships and Explores Islamic Finance Innovation at Exclusive Forum
-
Blockchain Press Releases7 days agoAfrica Exclusive: Bybit Promotes Crypto Education with P2P Security Webinar
-
Blockchain Press Releases4 days agoRequest Finance acquires Pay.so Lithuania; launches revolutionary one-click crypto/fiat payment solution.
-
Blockchain3 days agoThe GAM3 Awards 2024 Winners Announced
-
Blockchain2 days ago
Former MD of SUI Foundation, Greg Siourounis, Joins xMoney Global as Co-Founder and CEO to build MiCA-Regulated Stablecoin Platform
